Opendata, web and dolomites

AntiHelix SIGNED

DNA helicases in genome maintenance: from molecular and cellular mechanisms to specific inhibitors as potential drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AntiHelix project word cloud

Explore the words cloud of the AntiHelix project. It provides you a very rough idea of what is the project "AntiHelix" about.

translation    dimension    physiological    ubiquitous    young    eukaryotic    scientists    variety    found    molecule    remodel    revealed    science    inhibitors    biochemical    competence    generation    experts    source    oncology    motor    diseases    antiviral    instrumentation    job    clinical    expertise    mechanism    bacteria    training    separate    educate    market    molecular    dna    recombination    function    skills    enzymes    reproducibility    cancers    helicases    laboratories    mechanisms    implicated    date    cancer    accessibility    chemistry    commitment    competitive    rna    discover    transparency    repair    sectors    cells    relationships    companies    act    private    physics    biophysical    tested    discovery    archaea    diverse    protein    drug    picture    techniques    complementary    openness    academic    viruses    human    biology    antibiotic    coupled    duplexes    replication    class    cellular    structural    stage    reaction    structure    genetic    secondments    anti    integrity    drugs    proteins    energy    insights    play    obtain    culture    action    transport    therapeutic    full    of    single    functions    atp   

Project "AntiHelix" data sheet

The following table provides information about the project.

Coordinator
CONSIGLIO NAZIONALE DELLE RICERCHE 

Organization address
address: PIAZZALE ALDO MORO 7
city: ROMA
postcode: 185
website: www.cnr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 3˙508˙622 €
 EC max contribution 3˙508˙622 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) coordinator 522˙999.00
2    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 595˙044.00
3    ELETTRA - SINCROTRONE TRIESTE SCPA IT (BASOVIZZA TRIESTE) participant 522˙999.00
4    LEAD DISCOVERY CENTER GMBH DE (DORTMUND) participant 505˙576.00
5    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 303˙172.00
6    EDELRIS SAS FR (LYON) participant 274˙802.00
7    LUMICKS B.V. NL (AMSTERDAM) participant 265˙619.00
8    STICHTING VU NL (AMSTERDAM) participant 265˙619.00
9    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 252˙788.00

Map

 Project objective

Helicases are ubiquitous enzymes, found in viruses, Bacteria, Archaea and eukaryotic cells. They act as motor proteins to separate or remodel DNA or RNA duplexes, using ATP as an energy source. Helicases play a key role in a variety of cellular processes, including DNA replication/repair/recombination, as well as RNA translation and transport. They are emerging as an important class of targets for antiviral, antibiotic and anti-cancer drugs. To date, several genetic and biochemical studies have revealed the molecular and physiological functions of DNA helicases. Moreover, protein three-dimension structural studies coupled with single molecule biophysical approaches have provided insights into structure-function relationships and reaction mechanisms of some key DNA helicases. With a consortium including experts with complementary competence and expertise in Physics, Chemistry, Biology and Clinical Oncology, and a strong commitment of companies involved in drug discovery or in the development of state-of-the-art biophysical instrumentation, we aim to: 1. obtain a detailed picture of the mechanism of action and the physiological role of a number of DNA helicases that are implicated in human diseases; 2. discover specific inhibitors of those enzymes, which can then be tested as novel therapeutic drugs, especially for cancers; 3. address the need for training next generation scientists with complementary approaches and diverse techniques by secondments in different laboratories of the consortium; 4. promote a culture of collaboration between academic and private sectors and provide young scientists with the necessary experience and skills to exploit the full potential of research findings; 5. provide early stage researchers with greater opportunities to access an increasingly competitive job market; 6. promote the values of Open Science and educate young scientists on the importance of a culture of openness, transparency, accessibility, integrity and reproducibility.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTIHELIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANTIHELIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

HeatNMof (2020)

Heating triggered drug release from nanometric inorganic-metal organic framework composites

Read More